CREDO THERAPIES LTD - Profile & Financials

Accounts Submitted 24 Sept 2025

Confirmation Statement Submitted

Net assets £1.08M £1.45M 2024 year on year

Total assets £1.22M £1.37M 2024 year on year

Total Liabilities £145.77K £77.50K 2024 year on year

Charges None No charges registered

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

8 King Edward Street Oxford OX1 4HL United Kingdom

Website

credo-oxford.com

Credit Report

Discover CREDO THERAPIES LTD's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2023–2024)

Cash in Bank

£817.81k

Decreased by £1.47M (-64%)

Net Assets

£1.08M

Decreased by £1.45M (-57%)

Total Liabilities

£145.77k

Increased by £77.50k (+114%)

Turnover

N/A

Employees

Increased by 2 (+20%)

Debt Ratio

12%

Increased by 9 (+300%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2023 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

6 Allotments 307,985 Shares £33924.10m Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
12 May 2025	PRE-SEED PREFERRED 2	106,011	£10.601	£0
30 May 2023	PRE-SEED PREFERRED	42,404	£33923.20m	£800k
5 Dec 2022	ORDINARY	4,935	£75k	£15.198
5 Dec 2022	PRE-SEED PREFERRED	44,415	£675k	£15.198
1 Dec 2022	ORDINARY	100,350	£100.35	£0.001

Officers

5 active 3 resigned

Show resigned officers

						Status
Bruce Malcolm Gordon	Director	British	England	66	1 Sept 2025	Active
Joel Schoppig	Director	Swiss	United Kingdom	40	27 Mar 2024	Active
Lingyun Shao	Director	American	United States	48	1 Sept 2023	Active
Nicholas Joseph Mercadante	Director	American	United States	44	12 May 2025	Active
Rebecca Anne Murphy	Director	British	England	49	5 Dec 2022	Active

Shareholders

Shareholders (14)


Rebecca Anne Murphy	16.5%	34,375	Ordinary	6 Nov 2024
Seth Rankin	2.4%	4,935	Ordinary	6 Nov 2024
Rosalyn Breedy	0.8%	1,645	Ordinary	6 Nov 2024

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Oxford Science Enterprises Plc

United Kingdom

Active

Notified 5 Dec 2022

Nature of Control

Ownership Of Shares 50 To 75 Percent
Voting Rights 25 To 50 Percent

David James Bateman

Ceased 1 Dec 2022

Ceased

Cristian Oancea

Ceased 1 Dec 2022

Ceased

See All Controllers

Group Structure

OXFORD SCIENCE ENTERPRISES PLC united kingdom

CREDO THERAPIES LTD Current Company

Charges

No charges registered

Documents

Company Filings

Date	Category	Description	Document
24 Sept 2025	Accounts	Annual accounts made up to 2024-12-31	View(11 pages)
4 Sept 2025	Resolution	Resolutions	View(1 page)
4 Sept 2025	Incorporation	Memorandum Articles	View(56 pages)
3 Sept 2025	Officers	Appointment of Mr Bruce Malcolm Gordon as director on 2025-09-01	View(2 pages)
20 Jun 2025	Officers	Termination of David James Bateman as director on 2025-04-04	View(1 page)